BALTIMORE – The US generic industry may consider limiting the kind of original ANDAs eligible for FDA's priority assessment pathway when the generic drug user fee is renewed again, in part because the speedier assessment seems more valuable for ANDA amendments.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?